国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
Journal of International Oncology
2015年
11期
856-859
,共4页
肺肿瘤%综合疗法%放射疗法%药物疗法,联合%同步放化疗
肺腫瘤%綜閤療法%放射療法%藥物療法,聯閤%同步放化療
폐종류%종합요법%방사요법%약물요법,연합%동보방화료
Lung neoplasms%Combined modality therapy%Radiotherapy%Drug therapy,combination%Concurrent chemoradiation
同步放化疗已成为局部晚期NSCLC的主要治疗方式,然而其治疗前是否行诱导化疗仍存在较大争议,治疗后行巩固化疗所获得的生存优势尚未达成共识.目前认为,在初始化疗剂量不足时推荐加用巩固化疗.伴随着放疗技术的发展及化疗药物的更新,同步放化疗有望为局部晚期NSCLC患者带来更好的生存获益.
同步放化療已成為跼部晚期NSCLC的主要治療方式,然而其治療前是否行誘導化療仍存在較大爭議,治療後行鞏固化療所穫得的生存優勢尚未達成共識.目前認為,在初始化療劑量不足時推薦加用鞏固化療.伴隨著放療技術的髮展及化療藥物的更新,同步放化療有望為跼部晚期NSCLC患者帶來更好的生存穫益.
동보방화료이성위국부만기NSCLC적주요치료방식,연이기치료전시부행유도화료잉존재교대쟁의,치료후행공고화료소획득적생존우세상미체성공식.목전인위,재초시화료제량불족시추천가용공고화료.반수착방료기술적발전급화료약물적경신,동보방화료유망위국부만기NSCLC환자대래경호적생존획익.
Concurrent chemoradiation has been the main treatment of locally advanced non-small cell lung cancer (LA-NSCLC).However, there is a controversy whether giving the induction chemotherapy before treatment.The survival advantage of consolidation chemotherapy doesn't reach a consensus.When the dose of initial chemotherapy is insufficient, consolidation chemotherapy is necessary.With the development of radiotherapy and the renewal of the chemotherapy drugs, concurrent chemoradiation is expected to bring better survival benefit for the patients with LA-NSCLC.
